The global shortage of glucagon-like peptide-1 (GLP-1) receptor agonists, which are highly sought after as treatments for type 2 diabetes and obesity, is increasing. This deficit is attributed to the unexpected increase in demand for GLP-1 receptor agonists. This has caused significant harm to...
The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is found primarily on the surfaces of various cell types within the human body. This receptor specifically interacts with GLP-1, a key hormone that pla...
Obesity has become a global public health issue, with the number of overweight/obese individuals increasing annually. However, weight loss faces various difficulties and challenges. Incretin medications, represented by glucagon-like peptide-1 (GLP-1), have brought new hope in the battle against obesi...
Glucagon-like peptide-1 (GLP-1) has been the focus of considerable research activity in the treatment of type 2 diabetes mellitus (T2DM) because the incretin effect is significantly reduced or absent in individuals with T2DM. Thus, pharmacologic efforts to develop medications that mimic the actions...
glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of antidiabetic drugs noted not only for their potent glucose-lowering effects but also for their cardiovascular and renal protective benefits. Various GLP-1RAs have been demonstrated to have significant benefits in in vitro and in...
Glucagon-Like Peptide 1 Receptor Agonist GLP-1 agonists are medications used to treat type 2 diabetes mellitus in adults. They are sometimes referred to as incretin mimetics, GLP-1 analogs, or GLP-1 receptor agonists. A few drugs in this class are exenatide, lixisenatide, liraglutide, ...
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that promotes healthy insulin signaling, regulates blood sugar levels, and suppresses appetite. Consequently, numerous GLP-1 receptor (GLP-1R) stimulating drugs have been developed and approved by the US Food and Drug Administration (FDA) ...
Semaglutide, a Glucagon-like peptide 1 (GLP-1) receptor agonist marketed under the brand name Ozempic, is originally prescribed for diabetes treatment and obesity management. However, healthy individuals without a medical cause use Ozempic without medical supervision to improve their physical appearance ...
glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of antidiabetic drugs noted not only for their potent glucose-lowering effects but also for their cardiovascular and renal protective benefits. Various GLP-1RAs have been demonstrated to have significant benefits in in vitro and in...
Cigarette smoking is the leading preventable cause of premature death. Despite dedicated programmes, quit rates remain low due to barriers such as nicotine withdrawal syndrome or post-cessation weight gain. Glucagon-like peptide-1 (GLP-1) analogues reduc